Highly Validated Approaches to Highly Unmet Need. Developing Treatments for Severe Liver Disease.

At Inipharm, we’re building on novel insights and applying our chemistry expertise to develop therapies for patients with liver disease. Inipharm’s lead program is focused on small-molecules to target the activity of HSD17B13, a highly validated, genetically defined target for multiple severe liver and related diseases.

There is extensive evidence that certain variants of this gene are associated with lower rates of disease, less severe disease and reduced levels of liver damage, including inflammation and fibrosis. Inipharm is building on novel insights into the biologic activity of HSD17B13 to advance a collection of potent and selective small molecules that mimic the protective phenotype.